OnCo

Thymoma and thymic carcinoma: lines of therapy

Cancer page →

4 standard-of-care settings across 3 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineAll comers
Early / localised1
Locally advanced1
Second line2

Early / localised

SubgroupSettingApproachProducts and trialsEvidence
All comersResectable (stage I-III)Complete thymectomy (minimally invasive for small tumours) after myasthenia control; post-operative radiotherapy for stage III, R1/R2, or thymic carcinoma.91

Locally advanced

SubgroupSettingApproachProducts and trialsEvidence
All comersLocally advanced unresectableInduction chemotherapy (CAP or carboplatin-paclitaxel) then surgery if resectable, otherwise definitive radiotherapy ± chemotherapy.91

Second line

SubgroupSettingApproachProducts and trialsEvidence
All comersRecurrent thymomaRe-resection of pleural or local recurrence; chemotherapy; octreotide + prednisone if octreoscan-positive; everolimus.95
All comersRecurrent thymic carcinomaSunitinib or lenvatinib (REMORA); pembrolizumab (with strict cardiac monitoring, not in thymoma); everolimus; KIT inhibitors for KIT-mutant disease.98

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.